Mesoblast (NASDAQ:MESO) Stock Rating Upgraded by Jefferies Financial Group

Mesoblast (NASDAQ:MESO) was upgraded by investment analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a report issued on Thursday, MarketBeat reports.

Other analysts also recently issued reports about the stock. Piper Sandler upgraded shares of Mesoblast from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $4.00 to $11.00 in a research report on Tuesday, July 23rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a report on Thursday, June 20th. Finally, StockNews.com raised Mesoblast from a “sell” rating to a “hold” rating in a research note on Tuesday.

Mesoblast Trading Up 4.2 %

Mesoblast stock opened at $6.74 on Thursday. Mesoblast has a 12-month low of $1.61 and a 12-month high of $8.66. The firm has a market capitalization of $769.56 million, a price-to-earnings ratio of -6.02 and a beta of 3.48. The firm has a 50 day moving average of $6.84 and a 200 day moving average of $5.81.

Hedge Funds Weigh In On Mesoblast

Hedge funds have recently modified their holdings of the stock. Marshall Wace LLP bought a new stake in Mesoblast in the 2nd quarter valued at $562,000. Chase Investment Counsel Corp bought a new stake in shares of Mesoblast in the first quarter worth about $298,000. XTX Topco Ltd purchased a new stake in shares of Mesoblast in the second quarter worth about $103,000. Rathbones Group PLC purchased a new stake in shares of Mesoblast in the second quarter worth about $95,000. Finally, Pine Valley Investments Ltd Liability Co bought a new position in Mesoblast during the second quarter valued at approximately $80,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.